Upcoming event

Tags

Abiraterone, abiraterone acetate, ACP3 PET, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen deprivation therapy, Androgen pathway blockade, Androgen receptor inhibitor, Antiandrogens, Anticancer agents, apalutamide, ARCHES, Article of the Month, artificial intelligence, ASCO GU21, ASCO GU22, ASCO2026, ASCO21, ASCO26, AUA21, BHC80, Biochemical recurrence, biomarker, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, BRCA1, BRCA2, CAPItello-281, capivasertib, Castrate-resistanter, Castration-resistant, Chemotherapy, Clinical trial, Clinical trials, Cohort study, COVID-19, cSP, darolutamide, Deferred treatment, Diagnosis, Disease progression, Docetaxel, EAU21, EAU22, Emission-computed, EMUC21, EMUC22, End-to-side nerve grafting, Enzalutamide, Erectile dysfunction, Erectile function, ESMO21, ESMO22, ESOU Online, ESU Masterclass, ESU Masterclasses, External beam radiotherapy, Focal therapy, Frozen section, Fusion biopsies, Genomic classifier, Genomics, Guidelines, high-risk prostate cancer, homologous recombination repair, hormone-sensitive, HORRAD, HRQL, HRR-deficient mCSPC, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Intensity-modulated radiotherapy, Local radiotherapy, Localised, Localized, Localized prostate cancer, locally advanced prostate cancer, Lymph node excision, Lymphadenectomy, Mapping, Mass spectrometry, Masterclass, Masterclasses, mCSPC, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, metastatic castration-sensitive prostate cancer, metastatic hormone-sensitive prostate cancer, mHSPC, Mortality reduction, mp-MRI, MRI, Neoplasm staging, Nerve sparing, Next-generation sequencing, Nomogram, Noncastrate, Orchiectomy, Overdiagnosis, p53, Patient information, PCa21, PEACE-1 trial, pelvic lymph node dissection, Penile rehabilitation, PET/CT, Positron emission tomography, Precision medicine, prednisone, Pretreatment risk stratification, Pretreatment tables, Primary tumor treatment, PRIMARY2, Prognosis, Prognostic model, Prostasomes, prostate cancer, prostate cancer screening, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, ProtecT trial, Proteomics, PROTEUS study, PSA, PSA flare, PSA kinetics, PSA screening, PSMA, PSMA PET/CT, PTEN, PTEN deficiency, Quality of life, Radiation therapy, Radical prostatectomy, radioligand therapy, Randomized prospective trial, Randomized trial, Randomized trials, Rapid metastasis, Rb, RB1, Receptors, Risk stratification, RNA splicing, Robotic prostatectomy, Robotic surgery, Robotic Urology, Robotics, Salvage therapy, Screening, Sentinel lymph node, Sexual quality of life, SREs, SRRM4, STAMPEDE, Stereotactic body radiotherapy, Summer read, Surgical margins, Surgical video, Surgical videos, Systematic biopsy, Systematic review, TALAPRO-3 study, talazoparib, Targeted Biopsy, TITAN, TP53, Transcriptome, Transperineal template biopsy, Tumor suppressor genes, Ultrasensitive PSA, Urinary incontinence, Urological surgery, UROonco25, Urowebinar, WCRF/AICR CUP, Webinar, Wnt, Zoledronic acid
Show all

Third-line life-prolonging drug treatment in a real-world metastatic castration-resistant prostate cancer population: results from the Dutch castration-resistant prostate cancer registry

European Urology Focus, April 2020

Surgery associated with increased survival compared to radiation in clinically localized Gleason 9–10 prostate cancer: a SEER analysis

World Journal of Urology, April 2020

Olaparib for metastatic castration-resistant prostate cancer

The New England Journal of Medicine, April 2020

Prospective evaluation of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/ computed tomography in primary prostate cancer diagnosis

European Urology Focus, April 2020

Additional value of dynamic contrast-enhanced sequences in multiparametric prostate magnetic resonance imaging: data from the PROMIS Study

European Urology, April 2020

External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection

European Urology, April 2020

Changes in treatment and mortality in men with locally advanced prostate cancer between 2000‐2016. Nationwide, population‐based study in Sweden

BJU International, April 2020

Competing risks of mortality among men with biochemical recurrence after radical prostatectomy

Journal of Urology, April 2020

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: the ORIOLE phase 2 randomized clinical trial

JAMA Oncology, March 2020

Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier

Prostate Cancer and Prostatic Diseases, March 2020

Retzius-sparing robotic radical prostatectomy for surgeons in the learning curve: a propensity score–matching analysis

European Urology Focus, March 2020

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study

Lancet, March 2020

PreviousNext